亚洲知识产权资讯网为知识产权业界提供一个一站式网上交易平台,协助业界发掘知识产权贸易商机,并与环球知识产权业界建立联系。无论你是知识产权拥有者正在出售您的知识产权,或是制造商需要购买技术以提高操作效能,又或是知识产权配套服务供应商,你将会从本网站发掘到有用的知识产权贸易资讯。

Therapeutic and Diagnostic Application of Epicatechin in the Treatment of Cardiovascular and Inflammatory Disorders

技术应用
These findings can potentially be used in the treatment of heart failure, acute myocardial infarction, atrial fibrillation, and inflammations in the nervous system such as neurovascular and neurological disorders. In addition, epicatechin can be used to improve the exercise capacity in patients. Lastly, genetic testing can potentially be developed, using biomarkers such as B-type natriuretic peptide, myeloperoxidase, tumor necrosis factor, uric acid, ST2, choline, interleukin-6 or fatty acid proteins, to assess individual response to epicatechin treatment.
详细技术说明
UC San Diego researchers have discovered that flavanols, epicatechin in particular, protect the heart from ischemia-mediated injury by the way of reducing infarct size. Epicatechin has also demonstrated the capacity to ameliorate various indicators of tissue damage/inflammation in injured myocardium, as well as to limit the development of late adverse ventricular remodeling. Epicatechin is potentially the first compound to be able to reduce infarct size in the acute as well as chronic stage.
*Abstract
Ischemic heart disease is the leading cause of death for both men and women in the U.S. as well as other industrialized countries. Infarct size is hypothesized to be a major determinant of prognosis in the treatment of ischemic injuries. Therefore there is a need for a compound that the can not only reduce the infarct size in the acute stage of myocardial infarction but also in the chronic stage.
*IP Issue Date
Feb 11, 2014
*Principal Investigation

Name: Alan Maisel

Department:


Name: Pam Taub

Department:


Name: Francisco Villarreal

Department:


Name: Katrina Yamazaki

Department:

附加资料
Patent Number: US8648059B2
Application Number: US2010922170A
Inventor: Villarreal, Francisco | Yamazaki, Katrina Go | Taub, Pam Rajendran | Maisel, Alan
Priority Date: 13 Mar 2008
Priority Number: US8648059B2
Application Date: 15 Oct 2010
Publication Date: 11 Feb 2014
IPC Current: A61K003165
US Class: 514152 | 514154
Assignee Applicant: The Regents of the University of California
Title: Use of epicatechin and derivatives and salts thereof for cardiac protection of ischemic myocardium and to ameliorate adverse cardiac remodeling
Usefulness: Use of epicatechin and derivatives and salts thereof for cardiac protection of ischemic myocardium and to ameliorate adverse cardiac remodeling
Summary: The method for reducing infarct size in the heart following or during permanent ischemia or an ischemia/reperfusion event. The method is also used for reducing myocardial infarct size following myocardial infarction; for treating subarachnoid hemorrhage; for treating atrial fibrillation; and for delaying, attenuating or preventing adverse cardiac remodeling; for enhancing or preserving migration, seeding, proliferation, differentiation and/or survival of stem cells in injured heart tissue; for treating induced injury to heart or suffering from disease that results from insufficient growth and/or differentiation of stem cells and/or that compromises engraftment of cells in the heart; for treating or preventing ischemic/reperfusion injury; for inducing proliferation and/or survival of stem cells in a tissue; and for treating organ or tissue ischemia. The permanent ischemia or ischemia/reperfusion event is myocardial infarction, unstable angina, or acute coronary syndrome. The adverse cardiac remodeling comprises hypertrophy, thinning of myocardium, scar formation of myocardium, atrophy of myocardium, and/or heart failure progression. The subject suffers from Kawasaki disease, chronic hypertension, congenital heart disease with intracardiac shunting, congestive heart failure or valvular heart disease. The remodeling stems from coronary artery bypass surgery, cardiac transplant or receipt of a mechanical support device (preferably heart). The disease is ischemic injury, myocardial infarction, muscle ischemia, heart disease, congenital heart failure, and congestive heart failure. The organ or tissue ischemia event is acute/reperfusion event. The organ tissue ischemia event is caused by a condition of myocardial infarction, renal injury, total coronary occlusion, myocardial ischemia, stroke, aortic aneurysm, atrial fibrillation, and medical intervention causing temporary acute ischemia. The organ or tissue ischemia event is caused by coronary artery bypass graft surgery, aneurysm repair, angioplasty, or administering a radiocontrast agent. (all claimed).
主要类别
生物医学
细分类别
医药成分
申请号码
8648059
其他

State Of Development

The above-mentioned findings have been validated in the murine model and confirmed in a preliminary human study.


Related Materials

Taub PR, Ramirez-Sanchez I, Ciaraldi TP, Gonzalez-Basurto S, Coral-Vazquez R, Perkins G, Hogan M, Maisel AS, Henry RR, Ceballos G, Villarreal F. “Perturbations in skeletal muscle sarcomere structure in patients with heart failure and Type 2 diabetes: restorative effects of (-)-epicatechin rich cocoa.” Clin Sci (Lond). 2013 Oct 1;125(8):383-9. doi: 10.1042/CS20130023.
Ramirez-Sanchez I, Nogueira L, Moreno A, Murphy A, Taub P, Perkins G, Ceballos GM, Hogan M, Malek M, Villarreal F. “Stimulatory effects of the flavanol (-)-epicatechin on cardiac angiogenesis: additive effects with exercise.” J Cardiovasc Pharmacol. 2012 Nov; 60(5):429-38. doi: 10.1097/FJC.0b013e318269ae0d.
Yamazaki KG, Taub PR, Barraza-Hidalgo M, Rivas MM, Zambon AC, Ceballos G, Villarreal FJ. “Effects of (-)-epicatechin on myocardial infarct size and left ventricular remodeling after permanent coronary occlusion.” J Am Coll Cardiol. 2010 Jun 22; 55(25):2869-76. doi: 10.1016/j.jacc.2010.01.055.
Yamazaki KG, Romero-Perez D, Barraza-Hidalgo M, Cruz M, Rivas M, Cortez-Gomez B, Ceballos G, Villarreal F. Short- and long-term effects of (-)-epicatechin on myocardial ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol. 2008 Aug; 295(2):H761-7. doi: 10.1152/ajpheart.00413.2008. Epub 2008 Jun 20.


Tech ID/UC Case

23365/2008-197-0


Related Cases

2008-197-0

国家/地区
美国

欲了解更多信息,请点击 这里
移动设备